Dr. Paul B. Gilman
Claim this profileRiddle Memorial Hospital
Studies Cancer
Studies Non-Small Cell Lung Cancer
14 reported clinical trials
43 drugs studied
Area of expertise
1Cancer
Stage IV
KRAS positive
NRAS positive
2Non-Small Cell Lung Cancer
Stage IV
Stage III
EGFR positive
Affiliated Hospitals
Clinical Trials Paul B. Gilman is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Chemotherapy + Radiotherapy
for Esophageal and Gastric Cancer
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
More about Paul B. Gilman
Clinical Trial Related3 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Paul B. Gilman has experience with
- Paclitaxel
- Binimetinib
- Olaparib
- Carboplatin
- Osimertinib
- Selumetinib Sulfate
Breakdown of trials Paul B. Gilman has run
Cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Paul B. Gilman specialize in?
Paul B. Gilman focuses on Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are KRAS positive.
Is Paul B. Gilman currently recruiting for clinical trials?
Yes, Paul B. Gilman is currently recruiting for 11 clinical trials in Media Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Paul B. Gilman has studied deeply?
Yes, Paul B. Gilman has studied treatments such as Paclitaxel, Binimetinib, Olaparib.
What is the best way to schedule an appointment with Paul B. Gilman?
Apply for one of the trials that Paul B. Gilman is conducting.
What is the office address of Paul B. Gilman?
The office of Paul B. Gilman is located at: Riddle Memorial Hospital, Media, Pennsylvania 19063 United States. This is the address for their practice at the Riddle Memorial Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.